{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:11:34Z","timestamp":1766182294188},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"DOI":"10.7759\/cureus.59548","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:09:45Z","timestamp":1714702185000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Outcomes of Topical Bevacizumab for the Treatment of Corneal Neovascularization"],"prefix":"10.7759","author":[{"given":"Mohd Ihsan","family":"Jamaludin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Haslina","family":"Wan Abdul Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teck Chee","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-017-0094-6","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi S","year":"2017","unstructured":"Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis (Lond). 2017, 4:28. 10.1186\/s40662-017-0094-6","journal-title":"Eye Vis (Lond)"},{"key":"ref2","article-title":"Corneal neovascularization: updates on pathophysiology, investigations & management","volume":"63","author":"Sharif Z","year":"2019","unstructured":"Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019, 63:15-22.","journal-title":"Rom J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":"Novel aspects of corneal angiogenic and lymphangiogenic privilege","volume":"29","author":"Ellenberg D","year":"2010","unstructured":"Ellenberg D, Azar DT, Hallak JA, et al.. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 2010, 29:208-48. 10.1016\/j.preteyeres.2010.01.002","journal-title":"Prog Retin Eye Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati BK","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N, et al.. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006, 443:993-7. 10.1038\/nature05249","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas ES","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004, 351:2805-16. 10.1056\/NEJMoa042760","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease","volume":"25","author":"Adamis AP","year":"2005","unstructured":"Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005, 25:111-8. 10.1097\/00006982-200502000-00001","journal-title":"Retina"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara N","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005, 333:328-35. 10.1016\/j.bbrc.2005.05.132","journal-title":"Biochem Biophys Res Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/178132","article-title":"Treatment of corneal neovascularization using anti-VEGF bevacizumab","volume":"2014","author":"Krizova D","year":"2014","unstructured":"Krizova D, Vokrojova M, Liehneova K, Studeny P. Treatment of corneal neovascularization using anti-VEGF bevacizumab. J Ophthalmol. 2014, 2014:178132. 10.1155\/2014\/178132","journal-title":"J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13122-8","article-title":"Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B(4) receptor 2","volume":"7","author":"Iwamoto S","year":"2017","unstructured":"Iwamoto S, Koga T, Ohba M, et al.. Non-steroidal anti-inflammatory drug delays corneal wound healing by reducing production of 12-hydroxyheptadecatrienoic acid, a ligand for leukotriene B(4) receptor 2. Sci Rep. 2017, 7:13267. 10.1038\/s41598-017-13122-8","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.04.008","article-title":"Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization","volume":"79","author":"Castro MR","year":"2004","unstructured":"Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res. 2004, 79:275-85. 10.1016\/j.exer.2004.04.008","journal-title":"Exp Eye Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig Y","year":"2009","unstructured":"Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009, 247:1375-82. 10.1007\/s00417-009-1099-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi MH","year":"2009","unstructured":"Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al.. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009, 127:381-9. 10.1001\/archophthalmol.2009.18","journal-title":"Arch Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang JH","year":"2012","unstructured":"Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012, 57:415-29. 10.1016\/j.survophthal.2012.01.007","journal-title":"Surv Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin CT","year":"2010","unstructured":"Lin CT, Hu FR, Kuo KT, Chen YM, Chu HS, Lin YH, Chen WL. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci. 2010, 51:6277-85. 10.1167\/iovs.09-4571","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou M","year":"2008","unstructured":"Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008, 145:424-31. 10.1016\/j.ajo.2007.11.003","journal-title":"Am J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts","volume":"33","author":"Awadein A","year":"2007","unstructured":"Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007, 33:1991-3. 10.1016\/j.jcrs.2007.07.012","journal-title":"J Cataract Refract Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim SW","year":"2008","unstructured":"Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008, 115:e33-8. 10.1016\/j.ophtha.2008.02.013","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/243824-clinical-outcomes-of-topical-bevacizumab-for-the-treatment-of-corneal-neovascularization","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:09:48Z","timestamp":1714702188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/243824-clinical-outcomes-of-topical-bevacizumab-for-the-treatment-of-corneal-neovascularization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.59548","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}